Literature DB >> 12752474

Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures.

Kian-Ti Yu1, Sandra Mills, Nanora Thompson, Cedric Cunanan.   

Abstract

PURPOSE: To evaluate the safety and efficacy of intravenous valproate (VPA) loading in children with status epilepticus (SE) or acute repetitive seizures.
METHODS: Retrospective review was performed on 40 pediatric patients with intravenous VPA loading. Patients were classified into two groups: SE (n = 18) and acute repetitive seizures (n = 22). Thirty-one patients were VPA naïve and received a full loading dose of 25 mg/kg; nine had subtherapeutic plasma VPA levels and received a partial loading dose. Average infusion rate was 2.8 mg/kg/min. Heart rate and blood pressure were measured before, during, and after infusion.
RESULTS: Intravenous VPA loading stopped seizures in 18 patients with SE within 20 min. All 18 patients regained baseline mental status within 1 h of seizure cessation. Among 22 patients with acute repetitive seizures, only one had further seizures after VPA infusion. One patient in the SE group complained of transient tremors. No significant changes in blood pressure or heart rate were found in either group. Postinfusion plasma VPA levels ranged from 51 to 138 microg/ml (mean +/- SD = 88 +/- 21.5 microg/ml).
CONCLUSIONS: Intravenous VPA loading is safe and effective for treating acute seizure emergencies in children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12752474     DOI: 10.1046/j.1528-1157.2003.41302.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  21 in total

1.  The status of intravenous valproate for status.

Authors:  Lawrence J Hirsch
Journal:  Epilepsy Curr       Date:  2007 Jul-Aug       Impact factor: 7.500

Review 2.  Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.

Authors:  Pavla Pokorná; Karolina Hronová; Martin Šíma; Ondřej Slanař; Petr Klement; John N van den Anker; Dick Tibboel
Journal:  Eur J Clin Pharmacol       Date:  2017-02-06       Impact factor: 2.953

3.  Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo.

Authors:  Amine Achachi; Arnaud Florins; Nicolas Gillet; Christophe Debacq; Patrice Urbain; Germain Manfouo Foutsop; Fabian Vandermeers; Agnieszka Jasik; Michal Reichert; Pierre Kerkhofs; Laurence Lagneaux; Arsène Burny; Richard Kettmann; Luc Willems
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

Review 4.  Refractory generalised convulsive status epilepticus : a guide to treatment.

Authors:  Reetta Kälviäinen; Kai Eriksson; Ilkka Parviainen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Management of pediatric status epilepticus.

Authors:  Nicholas S Abend; Tobias Loddenkemper
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

6.  Attenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid.

Authors:  Xuehua Xu; Annette Müller-Taubenberger; Kathryn E Adley; Nadine Pawolleck; Vivian W Y Lee; Claudia Wiedemann; Talvinder S Sihra; Markus Maniak; Tian Jin; Robin S B Williams
Journal:  Eukaryot Cell       Date:  2007-04-13

Review 7.  Recent developments in the diagnosis and treatment of status epilepticus.

Authors:  Megan Selvitelli; Frank W Drislane
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

Review 8.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

9.  Intravenous levetiracetam as treatment for status epilepticus.

Authors:  Sascha Berning; Frank Boesebeck; Andreas van Baalen; Christoph Kellinghaus
Journal:  J Neurol       Date:  2009-05-15       Impact factor: 4.849

Review 10.  Status epilepticus in children.

Authors:  Rani K Singh; William D Gaillard
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.